A male neonate was born to a 35-year-old mother at an outside hospital at 39 1/7 weeks gestation via emergency cesarean section due to decreased fetal movements. The infant had respiratory distress secondary to meconium aspiration and was noted to have a large, distended abdomen at birth. Subsequent ultrasound confirmed hepatosplenomegaly with no evidence of liver mass or ascites. By report, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were initially within the reference intervals, but the patient had a prolonged INR (international normalized ratio) and hypoalbuminemia, supporting liver dysfunction. The infant was transferred to our institution for specialized care owing to hepatosplenomegaly, hypoglycemia, and coagulopathy of unknown etiology. On admission, the infant was additionally noted to be mildly pancytopenic, with increased lactate and ammonia. Initially, infectious etiologies were of primary concern given the history of meconium aspiration and the history of hepatosplenomegaly, which may be a presenting feature in patients with congenital infection. However, an extensive infectious disease workup was negative and included screens for hepatitis A, B, and C, HIV, herpes simplex virus, cytomegalovirus, EpsteinBarr virus, parvovirus, enterovirus, toxoplasmosis, and blood, urine, and stool cultures.
CASE DESCRIPTION
A male neonate was born to a 35-year-old mother at an outside hospital at 39 1/7 weeks gestation via emergency cesarean section due to decreased fetal movements. The infant had respiratory distress secondary to meconium aspiration and was noted to have a large, distended abdomen at birth. Subsequent ultrasound confirmed hepatosplenomegaly with no evidence of liver mass or ascites. By report, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were initially within the reference intervals, but the patient had a prolonged INR (international normalized ratio) and hypoalbuminemia, supporting liver dysfunction. The infant was transferred to our institution for specialized care owing to hepatosplenomegaly, hypoglycemia, and coagulopathy of unknown etiology. On admission, the infant was additionally noted to be mildly pancytopenic, with increased lactate and ammonia. Initially, infectious etiologies were of primary concern given the history of meconium aspiration and the history of hepatosplenomegaly, which may be a presenting feature in patients with congenital infection. However, an extensive infectious disease workup was negative and included screens for hepatitis A, B, and C, HIV, herpes simplex virus, cytomegalovirus, EpsteinBarr virus, parvovirus, enterovirus, toxoplasmosis, and blood, urine, and stool cultures.
Hemophagocytic lymphohistiocytosis (HLH), 3 although rare, was also a diagnostic consideration, as it can present with hepatosplenomegaly, coagulopathy, and pancytopenia, which were seen in this patient. However, the patient's pancytopenia resolved and the patient lacked additional features of HLH such as hypertriglyceridemia and hyperferritinemia.
Given the patient's presentation of hepatosplenomegaly, hypoglycemia, and increased lactate and ammonia, an inborn error of metabolism was also part of the initial differential diagnosis. To screen broadly for metabolic disorders, plasma amino acids, urine organic acids, and plasma acylcarnitines were ordered stat while newborn screen results were pending. The clinical team was then called by the laboratory regarding the urine organic acid screen results and informed that although the overall urine organic acid profile was unremarkable, they noted a significant additional peak that identified as vanillylmandellic acid (VMA), and recommended quantification by a more specific method if clinically indicated. VMA and homovanillic acid (HVA) are catecholamine metabolites that are increased in patients with catecholaminesecreting tumors such as neuroblastoma, pheochromocytoma, and other tumors of neural crest origin. Given the lack of a mass on imaging studies of this patient, a malignant process was not high on the differential. Despite this, the team proceeded with the recommendation to specifically quantify HVA and VMA given the lack of a diagnosis in this patient at the time. Specific quantification demonstrated substantial increases in both urine VMA (430 mg/g creatinine, reference interval, 0 -32.8 mg/g creatinine) and HVA (432.5 mg/g creatinine, reference interval, 0 -17.6 mg/g creatinine).
CASE DISCUSSION
Neuroblastoma is a developmental tumor presenting in young children that originates from immature sympathetic ganglion cells, with the capacity to synthesize and secrete catecholamines (1 ) . As the most common cancer in infants less than 1-year-old, about 700 new cases of neuroblastoma are reported each year in the US, with an average age of diagnosis around 1-2 years of age (www. cancer.org, 2015). Neuroblastoma, an extracranial cancer, can arise anywhere throughout the sympathetic nervous system, with the adrenal glands and abdomen/ retroperitoneum being the most common primary sites of origin (2 ) . In this patient with a distended abdomen, a primary tumor was never identified despite repeated im-aging studies-the only initial evidence hinting at the potential for neuroblastoma was the increase in catecholamine metabolites HVA and VMA in urine. Thus, neuroblastoma became part of the differential and a subsequent ultrasound-guided percutaneous liver biopsy was performed. Microscopic examination of the liver biopsy demonstrated metastatic neuroblastoma with approximately 75% of the liver parenchyma involved. It is estimated that only 1% of neuroblastoma cases have an unknown primary tumor site (3 ).
In neuroblastoma, neural crest cells forming the tumor mass express enzymes responsible for catecholamine (dopamine and norepinephrine) metabolism. Relevant catabolic products include HVA derived from dopamine and VMA derived from norepinephrine. Both HVA and VMA can be detected in urine in increased amounts in neuroblastoma patients. Although standard practice recommends measurement of these metabolites in 24-h urine collections, studies have demonstrated that measurement from single random urine samples provides equivalent results, and thus the challenges of obtaining 24-h collections from children can be avoided (4 ) . As biomarkers for the diagnosis of neuroblastoma, HVA, and VMA together have a high diagnostic specificity, ranging from 96% to Ͼ99% (4 ). The diagnostic sensitivity of these markers is more variable (66%-100%), with lower sensitivities in part attributed to patients with early stage disease and lower catecholamine-producing tumor burden leading to an increase in false negatives (4 ) .
Although urine catecholamines are increased in Ͼ90% of neuroblastomas, diagnostic criteria ultimately require histopathologic confirmation of tumor (1 ). Specifically, international criteria for diagnosis of neuroblastoma require either: a) unequivocal histologic evidence from tumor tissue with or without immunohistology, electron microscopy, or increased catecholamines or metabolites; or b) unequivocal histologic evidence from bone marrow and increases in catecholamines or their metabolites (5 ) . Following diagnosis, CT and/or MRI scans, bilateral bone marrow aspirates, and biopsies are recommended for assessment of the primary tumor and potential metastases. Additionally, because metaiodobenzylguanidine (MIBG) selectively concentrates in Ͼ90% of neuroblastomas, MIBG scintigraphy is also required for staging (6 ) . Currently there are 2 published consensus staging systems for neuroblastoma patients: the more widely used INSS (International Neuroblastoma Staging System) provides postsurgical staging guidelines, whereas the INRG (International Neuroblastoma Risk Group) staging system classifies neuroblastoma patients before treatment or surgery (see Tables 1  and 2 ) (5, 7 ) . Once disease stage is established, additional biological and clinical variables such as patient age, tumor histology and ploidy, and genetic abnormalities [most notably MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog) amplification] are used for further risk stratification (6 ) .
The main clinical presentation in this patient on admission was hepatomegaly. Hepatomegaly has a broad (8 ) .
In this case, primary consideration was given to sepsis, TORCH infections, and metabolic disorders. Ultimately, liver biopsy led to the diagnosis of an uncommon cause of hepatomegaly in a neonate-infiltration secondary to metastatic neuroblastoma. Clinical presentation in patients with neuroblastoma is highly variable but will generally fall into 1 of 3 clinical categories based on disease stage: localized tumors, metastatic disease, and 4S disease (6 ) . Stage 4S typically has a favorable prognosis and is unique amongst metastatic tumors in that it will often spontaneously regress without therapy (6 ) . However, infants Ͻ2 months old with stage 4S disease will often present with frank hepatomegaly secondary to rapidly progressive infiltration of the liver with neuroblastoma leading to respiratory compromise, renal dysfunction and coagulopathy (6, 9 ) . Therefore, in this patient, although a primary tumor was never identified, it was felt the patient was best classified as stage 4S due to age, hepatomegaly secondary to metastatic neuroblastoma, and no evidence of metastases in other organs.
CASE FOLLOW-UP
In this diagnostically challenging patient, the presence of increased VMA was initially noted on a urine organic acid screen, and a subsequent specific quantitative measurement recommended by the laboratory for both VMA and HVA was essential for alerting clinicians to the possibility of neuroblastoma. Diagnosis of neuroblastoma was ultimately confirmed due to the subsequent liver biopsy demonstrating extensive involvement by metastatic neuroblastoma with favorable histology and nonamplification of MYCN, and the patient was categorized as stage 4S as described previously. At the time of diagnosis, the patient was unstable and critically ill, intubated and sedated secondary to respiratory failure, with renal dysfunction, hepatic failure, and coagulopathy. Given the critical state of the patient, further staging (MIBG scan, bilateral bone marrow aspirates, and biopsies) was deferred to allow for immediate treatment of the neuroblastoma. Since there was concern that chemotherapy could worsen the patient's liver function, radiation therapy was initiated first to reduce disease burden and then chemotherapy with etoposide, carboplatin, cyclophosphamide, and doxorubicin was started shortly thereafter. While undergoing treatment, the patient's clinical course was complicated by acute kidney injury requiring hemodialysis, tumor lysis syndrome, worsening coagulopathy, bone marrow suppression secondary to chemotherapy, ascites, and urinary tract infection over the subsequent 3 months. Despite the difficult clinical course, measurements of urinary HVA and VMA decreased to 10.5 mg/g creatinine (reference: 0 -32.8 mg/g creatinine) and 39.8 mg/g creatinine (reference: 0 -17.6 mg/g creatinine), respectively, indicating a good response to radiation and chemotherapy. A second liver biopsy 3 months after diagnosis confirmed treatment efficacy, with the volume of neuroblastic cells reduced to only 2%-5% of the liver parenchyma. Additionally, a staging bone marrow biopsy demonstrated no evidence of neuroblastoma, and a MIBG scan showed no evidence of neuroblastoma outside the liver. At 5 months of age, the patient was stable enough for transfer to another care facility closer to home. 
POINTS TO REMEMBER
• Neuroblastoma is a tumor derived from neural crest cells which synthesize and metabolize catecholamines. Specifically, dopamine is catabolized to HVA and norepinephrine to VMA, and these metabolites are increased in most patients with neuroblastoma.
• Although increased VMA and/or HVA aids in the diagnosis of neuroblastoma, diagnosis is ultimately established based on histologic evidence from bone marrow biopsy or tumor tissue.
• Risk stratification of neuroblastoma patients is dependent on stage, patient age, tumor histology and ploidy, and genetic abnormalities, most notably MYCN amplification.
• Hepatomegaly in a neonate has a broad differential and common causes include biliary tract obstruction, congestive heart failure, drugs, maternal diabetes, malnutrition, metabolic disorders, parenteral nutrition, pseudohepatomegaly, sepsis, storage diseases, viral hepatitis, and TORCH infections.
• Stage 4S is a unique metastatic malignancy, with most patients typically having spontaneous regression without therapy despite dissemination to skin, liver and/or bone marrow. However, as in this case, stage 4S patients younger than 2 months of age will often present with massive hepatomegaly leading to respiratory compromise, renal dysfunction, and coagulopathy secondary to hepatic failure, and will require treatment to reduce disease burden in the liver.
